These types of cases are concerning for the FDA, particularly if the results themselves are inaccurate. ???If the BRCA-related risk assessment for breast or ovarian cancer reports a false positive, it could lead a patient to undergo prophylactic surgery, chemoprevention, intensive screening, or other morbidity-inducing actions,??? the letter warns.